Efficacy of anlotinib in the treatment of advanced non-small cell lung cancer

WEI Zhenyao; HUANGFU Juan; ZHANG Huihui

Abstract：Objective:To explore the therapeutic effect of anlotinib combined with pemetrexed+carboplatin regi-men in the treatment of advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor-tyro-sine kinase inhibitor(EGFR-TKI)acquired resistance.Methods:All 74 patients with advanced NSCLC with EGFR-TKI acquired resistance admitted to the hospital from December 2019 to December 2022 were selected as research sub-jects for retrospective study.37 patients who chose the treatment regimen of anlotinib+pemetrexed+carboplatin were classified into combined group,and 37 patients who chose the treatment regimen of pemetrexed+carboplatin were regarded as control group.The effective rate ORR,disease control rate,progression-free survival rate and overall survival rate before treatment and after 5 cycles of treatment,levels of serum related markers such as cytokeratin 19 soluble fragment(CYFRA21-1)and squamous cell carcinoma antigen(SCC)after 3 cycles of treatment were com-pared between the two groups of patients.Results:Before treatment,the levels of SCC and CYFRA21-1 in both groups were similar(P＞0.05).After treatment,the levels of SCC and CYFRA21-1 in the two groups were signifi-cantly decreased compared with those before treatment(P＜0.05),and the levels in combined group were significantly lower than those in control group(P＜0.05).The disease control rate was significantly higher than that in control group(P＜0.05).The progression-free survival rate,overall survival rate and CTCAE evaluation results of chemo-therapy were similar in the two groups(P＞0.05).Conclusion:The combination of anlotinib and pemetrexed+carbo-platin regimen in treating advanced NSCLC patients with EGFR-TKI acquired resistance can play a significant anti-tumor effect,and the drug regimen has high safety,so it is recommended to be widely used in clinical practice.